Browse All / Modules / Gout Urate Crystal Inflammation Module

Gout Urate Crystal Inflammation Module

Module gout_urate_crystal_inflammation 1 disorder Pathograph 5
A conserved pathophysiology module representing the monosodium urate (MSU) crystal arthropathy pathway that produces gout. Sustained hyperuricaemia, arising from urate overproduction or, more commonly, renal and intestinal urate underexcretion mediated by urate transporters (URAT1, ABCG2), raises serum urate above its solubility limit. Supersaturation drives MSU crystal nucleation and deposition in joints and periarticular tissues; deposited crystals are phagocytosed by resident macrophages and engage the caspase-1-activating NLRP3 inflammasome, releasing bioactive interleukin-1 beta. IL-1 beta then drives acute neutrophil-rich inflammation, and recurrent crystal-driven flares progress to chronic tophaceous arthritis with erosive joint damage. Conforming disorder nodes substitute disorder-specific drivers of hyperuricaemia (enzymatic overproduction such as HPRT deficiency, or transporter-mediated underexcretion) while preserving the conserved crystal-deposition, inflammasome, and neutrophilic-inflammation chain.
⚙

Pathophysiology Nodes

5
5 shared nodes are defined in this module.
◉

Cell Types

2
Macrophage CL:0000235 Neutrophil CL:0000775
⇄

Biological Processes

5
Urate Metabolic Process GO:0046415 DYSREGULATED Purine Nucleotide Catabolic Process GO:0006195 INCREASED Interleukin-1 Beta Production GO:0032611 INCREASED Inflammatory Response GO:0006954 INCREASED Neutrophil Chemotaxis GO:0030593 INCREASED
i

Notes

This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "gout_urate_crystal_inflammation#NLRP3 Inflammasome Activation"). The module defines the expected pathophysiology structure; conforming nodes in disorder files should include the corresponding cell types, biological processes, and causal edges, specialized to their disease context. Key disease-specific substitutions: primary gout uses transporter-mediated urate underexcretion (URAT1/ABCG2); enzymatic overproduction syndromes (e.g., HPRT1 deficiency / Lesch-Nyhan, PRPP synthetase superactivity) substitute the overproduction driver at the trigger node. Urate chemistry is described in prose only; modules bind GO and CL terms only and do not use chemical (CHEBI) term bindings.
↗

Used By Disorder Entries

1
Gout via Inflammasome Activation → NLRP3 Inflammasome Activation
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence-backed metadata.
Pathograph: causal mechanism network for Gout Urate Crystal Inflammation Module Interactive directed graph showing how this shared module's pathophysiology nodes connect.
⚙

Pathophysiology

5
Hyperuricaemia
trigger
Serum urate rises above its physiological solubility limit owing to urate overproduction (increased purine turnover and xanthine oxidoreductase activity) and/or underexcretion. Renal and intestinal urate handling by membrane transporters is the dominant determinant: reduced secretion or increased reabsorption via URAT1, ABCG2, GLUT9, and related carriers elevates the urate pool. Sustained hyperuricaemia is the necessary upstream state for monosodium urate crystal formation.
Urate Metabolic Process GO:0046415 DYSREGULATED Purine Nucleotide Catabolic Process GO:0006195 INCREASED
Downstream
  • MSU Crystal Deposition
MSU Crystal Deposition
amplifier
Once serum urate exceeds its saturation point, monosodium urate supersaturates and nucleates into needle-shaped MSU crystals that deposit in and around joints and periarticular tissues. Crystal deposition is the pivotal step that converts the metabolic state of hyperuricaemia into a tissue lesion capable of provoking inflammation, and accumulated deposits seed both acute flares and chronic tophi.
Downstream
  • NLRP3 Inflammasome Activation
NLRP3 Inflammasome Activation
central effector
Deposited MSU crystals are phagocytosed by resident and recruited macrophages and act as a danger signal that engages the caspase-1-activating NLRP3 inflammasome. Inflammasome assembly activates caspase-1, which cleaves pro-IL-1 beta into bioactive IL-1 beta (and IL-18). This is the central effector step that transduces an inert crystal deposit into a potent pro-inflammatory cytokine signal, and is conserved across disorders producing MSU crystals.
Macrophage CL:0000235
Interleukin-1 Beta Production GO:0032611 INCREASED
Used by disorders
Gout as Inflammasome Activation
Downstream
  • IL-1-Driven Neutrophilic Inflammation
IL-1-Driven Neutrophilic Inflammation
effector
Bioactive IL-1 beta released after inflammasome activation acts on IL-1 receptors on endothelial and resident cells to drive an acute inflammatory response, with massive recruitment and activation of neutrophils into the affected joint. Neutrophil influx and the resulting cytokine and chemokine amplification produce the intense pain, swelling, and erythema of the acute gout flare. IL-1 receptor signalling is required for the crystal-induced neutrophilic response.
Neutrophil CL:0000775
Inflammatory Response GO:0006954 INCREASED Neutrophil Chemotaxis GO:0030593 INCREASED
Downstream
  • Recurrent and Chronic Tophaceous Gout
Recurrent and Chronic Tophaceous Gout
consequence
Repeated crystal-driven inflammatory flares present as acute, self-limiting monoarthritis. With persistent crystal deposition and unresolved hyperuricaemia, disease progresses to chronic inflammation, formation of tophi (organized aggregates of MSU crystals surrounded by inflammatory cells), and erosive damage to cartilage and bone with long-term functional impairment. This is the clinical phenotype of gout, the consequence of the conserved crystal-inflammation chain.